Theorem Clinical Research

R&D Trends

Science for Life Laboratory forms Swedish National Center

Monday, February 9, 2015 12:09 PM

Science for Life Laboratory (SciLifeLab) has established the Swedish National Center for Single-Cell Biology. The center features six C1TM systems, three CyTOF 2 systems and a Biomark HD system, making SciLifeLab one of the preeminent users of the full line of Fluidigm’s single-cell technologies in the world. Fluidigm develops, manufactures and markets life science analytical and preparatory systems for growth markets such as single-cell biology and production genomics. Fluidigm products are provided for research use only.

More... »

Quest Diagnostics

Exact Sciences, Mayo Clinic extend, expand collaboration

Monday, February 9, 2015 12:06 PM

Exact Sciences, a Madison, Wis.-based molecular diagnostics company, and Rochester, Minn.-based Mayo Clinic have announced a five-year extension and expansion of their collaboration, broadening their efforts to develop screening, surveillance and diagnostic tests beyond colorectal cancer to address other diseases within the gastrointestinal tract.

More... »


Lurie Cancer Center, NMDTI, Northwestern Memorial launch new research program

Friday, February 6, 2015 12:25 PM

The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, in collaboration with the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) and Northwestern Memorial Hospital, has launched a new research program, Northwestern Onco-SET (Sequence, Evaluate, Treat), to provide a more personalized, precision medicine option for cancer patients by combining oncology with genomics. This program initially will focus on patients with any type of cancer that is not responsive to traditional therapies.

More... »

Theravance Biopharma, Mylan partner for COPD

Wednesday, February 4, 2015 01:43 PM

Theravance Biopharma, based in south San Francisco, Calif., and Mylan, a global generic and specialty pharmaceuticals company headquartered in Cecil Township, Pa., will partner on the development and commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD) and other respiratory diseases.

More... »

COMBACTE-MAGNET launched to revitalize antibiotic development

Wednesday, February 4, 2015 01:41 PM

Thirty-three European academic partners and five pharmaceutical companies are launching a new project, COMBACTE-MAGNET, under the Innovative Medicines Initiative (IMI) antimicrobial resistance research program New Drugs 4 Bad Bugs (ND4BB).

More... »

EMD Millipore inks agreement with Precision Biologics

Monday, February 2, 2015 02:00 PM

EMD Millipore, the life science business of Merck of Darmstadt, Germany, has announced an agreement for providing upstream process development services for Precision Biologics, a Texas-based clinical-stage biotechnology company, to advance a preclinical monoclonal antibody. The antibody, NEO-201, binds to a tumor-specific antigen found in several forms of cancer, offering therapeutic potential across multiple cancer types, including colorectal, lung, ovarian and pancreatic, an especially deadly cancer with limited treatment options.

More... »

AstraZeneca, MD Anderson collaborate for ovarian/gynecologic cancers

Monday, February 2, 2015 01:50 PM

AstraZeneca and the University of Texas MD Anderson Cancer Center have announced a multi-year, strategic research collaboration to conduct multiple, parallel clinical and clinically-related studies in ovarian and other gynecologic cancers with the aim of improving patient outcomes.

More... »

U.K. announces $21M investment in stratified medicine

Friday, January 30, 2015 12:29 PM

Minister for Life Sciences George Freeman has announced a further $20.6 million investment in stratified medicine collaborations funded by the Medical Research Council (MRC). Four new awards bring the total of stratified medicine consortia funded by the MRC to 13, with investments totaling over $21 million—part of the government’s $195.4 million commitment to stratified medicine set out in the U.K. life sciences strategy.

More... »

Astellas Pharma, Immunomic Therapeutics collaborate

Friday, January 30, 2015 12:25 PM

Immunomic Therapeutics, a company developing next-generation vaccines based on the LAMP-vax platform headquartered in Hershey, Pa., and Astellas Pharma of Tokyo have entered into an exclusive license agreement for Japan to develop and commercialize JRC2-LAMP-vax, Immunomic Therapeutics' vaccine designed to treat allergies induced by Japanese red cedar pollen. The companies expect to initiate a phase I trial of JRC2-LAMP-vax in Japan as soon as it is ready.

More... »

Sigma-Aldrich, VIB ink alliance on novel translational research tools

Friday, January 23, 2015 11:46 AM

Sigma-Aldrich's research business unit, which supports translational researchers by supplying the products, services and solutions needed to enable scientific discovery, has formed an alliance with VIB, a life science research institute based in Flanders, Belgium, focused on translational research in medical, agricultural and industrial applications. The alliance will focus on the commercialization and supply of new tools and technologies to help meet the evolving needs of translational researchers.

More... »

AiCure
CWWeekly

March 23

Industry welcomes FDA draft guidance outlining the use of electronic Informed Consent for trials

Apple launches ResearchKit platform to tap millions of iPhone users to enroll in observational studies using apps

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs